Table of Contents
Metal-Based Drugs
Volume 5, Issue 2, Pages 77-81

Calcium Modulation of Toxicities Due to Cisplatin

Department of Zoology, Michigan State University, East Lansing 48823-1115, Michigan, USA

Received 12 January 1998; Accepted 2 February 1998

Copyright © 1998 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cisplatin (CDDP) is a potent anti-neoplastic agent with associated toxicities, especially gastrointestinal and nephrotoxicity that are its dose-limiting factors in clinical oncology. In an attempt to elucidate its mechanism(s) of action, liver and kidney tissues from normal and CDDP treated (1.8 mg/kg) dogs were evaluated for changes in various dehydrogenases [MDH, SDH, β-HBDH, IDH and G-6-PDH] and nonspecific lipase enzymes. CDDP treatment induced an inhibition of all the enzymes studied except G-6-PDH and nonspecific lipases, where there was a significant increase. Supplemental pretreatments with calcium 2.50 mg (150,000 USP units) ergocalciferol plus 1000 mg of elemental calcium as Tums 500 (EffeCal; calcium carbonate)/day seemed to retain enzyme levels close to normal with no apparent toxic side effects observed after CDDP. Calcium supplements post-CDDP treatment did not have any protective effect.